← Back to Search
Statins, High-density Lipoprotein Cholesterol, And Regression Of Coronary Atherosclerosis.
S. Nicholls, E. M. Tuzcu, I. Sipahi, A. W. Grasso, P. Schoenhagen, T. Hu, K. Wolski, T. Crowe, M. Desai, S. Hazen, S. Kapadia, S. Nissen
Published 2007 · Medicine
Download PDFAnalyze on Scholarcy
CONTEXT Statins reduce low-density lipoprotein cholesterol (LDL-C) levels and slow progression of coronary atherosclerosis. However, no data exist describing the relationship between statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and disease progression. OBJECTIVE To investigate the relationship between changes in LDL-C and HDL-C levels and atheroma burden. DESIGN, SETTING, AND PATIENTS Post-hoc analysis combining raw data from 4 prospective randomized trials (performed in the United States, North America, Europe, and Australia between 1999 and 2005), in which 1455 patients with angiographic coronary disease underwent serial intravascular ultrasonography while receiving statin treatment for 18 months or for 24 months. Ultrasound analysis was performed in the same core laboratory for all of the studies. MAIN OUTCOME MEASURE Relationship between changes in lipoprotein levels and coronary artery atheroma volume. RESULTS During statin therapy, mean (SD) LDL-C levels were reduced from 124.0 (38.3) mg/dL (3.2 [0.99] mmol/L) to 87.5 (28.8) mg/dL (2.3 [0.75] mmol/L) (a 23.5% decrease; P<.001), and HDL-C levels increased from 42.5 (11.0) mg/dL (1.1 [0.28] mmol/L) to 45.1 (11.4) mg/dL (1.2 [0.29] mmol/L) (a 7.5% increase; P<.001). The ratio of LDL-C to HDL-C was reduced from a mean (SD) of 3.0 (1.1) to 2.1 (0.9) (a 26.7% decrease; P<.001). These changes were accompanied by a mean (SD) increase in percent atheroma volume from 39.7% (9.8%) to 40.1% (9.7%) (a 0.5% [3.9%] increase; P = .001) and a mean (SD) decrease in total atheroma volume of 2.4 (23.6) mm3 (P<.001). In univariate analysis, mean levels and treatment-mediated changes in LDL-C, total cholesterol, non-HDL cholesterol, apolipoprotein B, and ratio of apolipoprotein B to apolipoprotein A-I were significantly correlated with the rate of atherosclerotic progression, whereas treatment-mediated changes in HDL-C were inversely correlated with atheroma progression. In multivariate analysis, mean levels of LDL-C (beta coefficient, 0.11 [95% confidence interval, 0.07-0.15]) and increases in HDL-C (beta coefficient, -0.26 [95% confidence interval, -0.41 to -0.10]) remained independent predictors of atheroma regression. Substantial atheroma regression (> or =5% reduction in atheroma volume) was observed in patients with levels of LDL-C less than the mean (87.5 mg/dL) during treatment and percentage increases of HDL-C greater than the mean (7.5%; P<.001). No significant differences were found with regard to clinical events. CONCLUSIONS Statin therapy is associated with regression of coronary atherosclerosis when LDL-C is substantially reduced and HDL-C is increased by more than 7.5%. These findings suggest that statin benefits are derived from both reductions in atherogenic lipoprotein levels and increases in HDL-C, although it remains to be determined whether the atherosclerotic regression associated with these changes in lipid levels will translate to meaningful reductions in clinical events and improved clinical outcomes.
This paper references
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
S. Grundy (2001)
Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial
J. Otvos (2006)
An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro
M. Aikawa (2001)
GEMFIBROZIL FOR THE SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MEN WITH LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL
An HMGCoAreductase inhibitor, cerivastatin, suppressesgrowth ofmacrophagesexpressingmatrixmetalloproteinasesand tissue factor in vivo and in vitro
M Aikawa (2001)
Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
S. Nissen (2004)
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
S. Grundy (2004)
Pharmacotherapy for dyslipidaemia – current therapies and future agents
H. Bays (2003)
HelsinkiHeartStudy : primary - prevention trialwithgemfibrozil inmiddle - aged men with dyslipidemia : safety of treatment , changes in risk factors , and incidence of coronary heart disease
EloO FrickMH (1987)
Scandinavian Simvastatin Survival Study Group
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A. Keech (2005)
Atherosclerosis--an inflammatory disease.
Kenny J. Williams (1999)
Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.
A. Plump (1994)
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
P. Canner (1986)
MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial.
S. Feasson (2008)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
F. Sacks (1996)
Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes: New Evidence for Direct Antiinflammatory Effects of Statins
C. Arnaud (2005)
Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study
G. Luc (2002)
Reading is important. Read between the lines—don't swallow everything. —Gwendolyn Brooks
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
S. Nissen (2006)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Scandinavian Simvastatin Survival Study Group (1994)
HelsinkiHeartStudy : primaryprevention trialwithgemfibrozil inmiddleaged men with dyslipidemia : safety of treatment , changes in risk factors , and incidence of coronary heart disease
PL Canner (1987)
Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study
S. Okazaki (2004)
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
S. Nissen (2004)
Antiinflammatory Properties of HDL
P. Barter (2004)
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
A. Taylor (2008)
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
M. Brousseau (2004)
Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialKeech A, and the FIELD study investigators (Univ of Sydney, Australia; et al) Lancet 366:1849–1861, 2005§
W. Frishman (2007)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes*
M. Miller (2004)
Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).
J. Stamler (1986)
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
S. Grundy (2002)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
J. Larosa (2005)
Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.
J. Badimon (1990)
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.
Bezafibrate Infarction Prevention study (2000)
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
G. Martin (2001)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
J. Auer (2004)
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins
A. Taylor (2004)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
J. R. Downs (1998)
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
S. Nissen (2005)
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
T. Pedersen (2005)
Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia
R. Milani (1996)
Simvastatin and niacin, antioxidant vitamins, or the combination STATINS, LIPIDS, AND CORONARY ATHEROMA REGRESSION ©2007 American Medical Association
BG Brown (2007)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
A. Tonkin (1998)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.
S. Nissen (2003)
Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
M. Guerin (2000)
Effect of ACAT inhibition on the progression of coronary atherosclerosis.
S. Nissen (2006)
The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes.
K. Ray (2005)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
J. Shepherd (1995)
American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
G. Mintz (2001)
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
Diabetes Atherosclerosis Intervention Study Investigators (2001)
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
M. Frick (1987)
El tratamiento hipolipemiante intensivo frente al moderado con estatinas tras síndromes coronarios agudos
C. Cannon (2004)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.
T. Pedersen (2004)
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
B. Brown (2001)
C-reactive protein levels and outcomes after statin therapy.
P. Ridker (2005)
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary
S. Yusuf (2002)
Regression of Coronary Atherosclerosis by Simvastatin: A Serial Intravascular Ultrasound Study
L. Jensen (2004)
This paper is referenced by
L'imaging della placca vulnerabile
G. Guagliumi (2010)
Short Communication: Dating Components of Human Atherosclerotic Plaques
Isabel Gonçalves (2010)
Multi detector-row computed tomographyにて冠動脈有意狭窄病変のない症例の予測因子についての検討
俊介 木内 (2012)
Angioscopic assessment for post coronary bypass saphenous vein diseases: ～内視鏡所見による検討～
Mitsumasa Hata (2017)
Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions.
Kyle D. Buchanan (2017)
A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach
L. Yan (2014)
The Evaluation of Chinese Therapeutic Food for the Treatment of Moderate Dyslipidemia
S. Sun (2012)
Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.
T. Korolenko (2012)
Morphological Changes of Parotid Gland in Experimental Hyperlipidemia
Ioanna D. Daskala (2011)
Medicinal Uses of Soil Components, Geophagia and Podoconiosis
R. Nieder (2018)
The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications
J. Feig (2016)
Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia.
K. Mizuno (2012)
HDL‐C Levels and Revascularization Procedures in Coronary Heart Disease Patients Treated With Statins to Target LDL‐C Levels
A. Elis (2011)
Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.
S. Voros (2010)
Cocientes lipoproteicos: significado fisiológico y utilidad clínica de los índices aterogénicos en prevención cardiovascular
J. Millán (2010)
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
G. Fabbri (2009)
High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome.
C. Cannon (2007)
The strengths and limitations of the ApoB/ApoA-I ratio to predict the risk of vascular disease: a hegelian analysis
A. Sniderman (2007)
Treatment of low high-density lipoprotein cholesterol
Z. Awan (2008)
Best Practice & Research Clinical Endocrinology & Metabolism
B. Stratmann (2009)
Gene-activators prevent and regress atherosclerosis and reduce mortality.
Pauli V. Luoma (2009)
Fitness level and physical capacity of commuter cyclists and the actual condition while cycling to work in Tokai region
Takumi Nishii (2012)
Calculated parameters of the lipidogram: modern scientific views and correlations with laboratory and instrumental indexes
Larysa Strilchuk (2017)
Plasma kallikrein contributes to ambient particulate matter-induced lung injury.
B. Wang (2019)
Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease.
M. Abe (2011)
Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1
D. He (2018)
Androgenic anabolic steroid abuse and the cardiovascular system.
P. Vanberg (2010)
ФАРМАКОЛОГИЧЕСКАЯ КОРРЕКЦИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ И АТЕРОГЕННЫХ ПОВРЕЖДЕНИЙ: ВОЗМОЖНОСТИ ВОССТАНОВЛЕНИЯ СТРУКТУРЫ И МЕТАБОЛИЗМА СЕРДЕЧНОЙ МЫШЦЫ
E. I. Yuzhik (2013)
Effects on Coronary Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol with Statins
J. Ferrières (2009)
Prevention of Lesion Recurrence in Endovascular Devices
A. Rochier (2010)
Cholesterol: The Good, the Bad, and the Ugly – Therapeutic Targets for the Treatment of Dyslipidemia
N. Elshourbagy (2013)
Srce i krvni Sudovi
B. Beleslin (2013)See more